ArticleProteins2026
Structural Insights Into the Function of Leishmania major Adenylosuccinate Lyase.
Article in Proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
One of several intriguing aspects of kinetoplastid biochemistry is the complete dependence on host purines and purine recycling due to the lack of a de novo purine biosynthesis pathway. Adenylosuccinate lyase (ASL, EC 4.3.2.2) is a key enzyme in the purine synthesis pathway responsible for the conversion of adenylosuccinate into adenosine monophosphate (AMP), representing a potential target for an effective drug design against leishmaniasis. Here, we report the in vitro kinetics studies and the crystal structure of the Leishmania major Friedlin adenylosuccinate lyase (LmASL). Furthermore, we characterize allosteric communication networks within the protein. We propose a phenylpiperazine derivative, itraconazole, as a promising candidate for selective interaction with the LmASL substrate-binding site by molecular docking and molecular dynamics simulations. Finally, we expand the current understanding on trypanosomatid ASL by demonstrating its requirement for the normal growth of Trypanosoma brucei procyclic form. Our data will substantiate future studies aimed at developing an effective and specific treatment against leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.